Zimmer Biomet Holdings Inc. stock rises 1.46% and outperforms competitors

13 articles · Updated · MarketWatch · Apr 27

Shares closed at $92.59 on Monday, breaking a two-day losing streak with trading volume reaching 2.5 million, above the 50-day average.
Zimmer Biomet outperformed major rivals as Johnson & Johnson fell 0.95%, Medtronic dropped 0.48%, and Stryker gained 0.46%.
Despite the gain, Zimmer Biomet remains 14.5% below its 52-week high of $108.29 set in August 2025, amid a mixed overall market session.

With earnings due, is Zimmer Biomet's stock surge a sign of strength or a bull trap for investors?

Can Zimmer Biomet's ROSA system win the orthopedic robotics war against Stryker's dominant Mako?

How will the boom in outpatient surgery centers reshape the profits of medical device giants?

Will a $1.5 billion stock buyback be enough to overcome concerns about the company's long-term growth?

Beyond knees, what is the next major frontier for surgical robotics in the orthopedics industry?